May 11, 2026
•
5 min read
Plus: Young AI talent shuns pharma, DeepMind’s AlphaEvolve reaches genomics, and Kanvas maps the microbiome.
May 7, 2026
7 min read
Plus: ARPA-H’s AI research engine, digital twins for donor lungs, and OpenBind’s new drug-design dataset
May 4, 2026
6 min read
Plus: a world model that simulates drug and lifestyle interventions person by person, perturbation prediction clears the bar, and a physics lab trains one model on DNA, RNA, and protein.
May 2, 2026
3 min read
Billion-dollar deals, enzymes nature never made, and virtual patients built from 7.2 million real ones.
Apr 29, 2026
Plus: Lilly’s $2.25B bet on AI-designed gene insertion, a literature agent that reads the pictures, and the FDA takes aim at the clinical trial bottleneck.
Apr 26, 2026
8 min read
Eight signals to help you understand what is actually happening beneath the weekly flood of papers, deals, tools, and demos.
Plus: a 24-year-old redesigns Keytruda, breast cells have a hidden “mechanical age,” and OpenAI gives its models to every US clinician for free.
Apr 23, 2026
Plus: virtual patients from 7.2 million real ones, AI antibiotics vs. reality, and clinical biomarkers hiding in your smartwatch.
Apr 19, 2026
Plus: OpenAI ships its first biology model and signs Novo Nordisk, a step toward virtual cells that explain the biology, and a brain-reading beanie with 100,000 sensors.
Apr 16, 2026
Plus: Goodfire takes on two million variants stuck in diagnostic limbo, AWS enters AI drug design, and five things the head of Isomorphic Labs told me
